-
Capital, M&A & Industry Strategy1 month ago8 biotech IPO prospects testing investor appetite
Fresh filings and older proposals reveal different tests of clinical evidence, financing needs and readiness for public ownership.
-
Capital, M&A & Industry Strategy1 month agoEli Lilly dishes out fresh produce to cultivate Alzheimer’s awareness
Eli Lilly is marking World Alzheimer’s Day with a partnership to distribute 13,500 boxes of brain-healthy fresh produce and educational materials to underserved senior populations across...
-
Capital, M&A & Industry Strategy1 month ago
After one failed acquisition attempt, Lisata finds lifeline in Marea merger
After a failed merger that led to massive layoffs and a lawsuit, solid tumor biotech Lisata Therapeutics has found a new future through a merger with...
-
Capital, M&A & Industry Strategy1 month ago
North Immunology goes public via reverse merger as eczema drug heads toward clinic
North Immunology has decided its path to taking an atopic dermatitis drug into the clinic involves going public via a reverse merger.
-
Capital, M&A & Industry Strategy1 month ago
Ex-PHM CEO Andrea Palmer takes top job at Assembled Intelligence
Former Publicis Health Media CEO Andrea Palmer has revealed her next post. The executive has taken the CEO position at Assembled Intelligence, the agency that Minds...
-
Capital, M&A & Industry Strategy1 month agoSleep deals cluster in narcolepsy and sleep apnea
BIOCENTURY | DATA BYTESLEEP DEALS CLUSTER IN NARCOLEPSY AND SLEEP APNEANarcolepsy drives the biggest transactions, while venture financing across the sleep field remains sparse
-
Capital, M&A & Industry Strategy1 month agoNovartis to pay $125M for blood-brain barrier crossing platform
Proceeds from the deal, which hands Novartis global rights to a technology developed by Sironax, will help advance three candidates that the startup says have “best-in-class”...
-
Capital, M&A & Industry Strategy1 month agoGilead and PAHO agree to expedite lenacapavir access for HIV prevention
The arrangement offers a new regional pathway for long-acting HIV prevention in all PAHO Member States through its Regional Revolving Funds. The collaboration enables 14 countries,...
-
Capital, M&A & Industry Strategy1 month agoEli Lilly and QurCan sign genetic medicine deal
The companies intend to work together on several research programmes focused on QurCan’s Target-Engineered Responsive Polymer (TERP) polymer-lipid nanoparticle (PLNP) delivery platform development. QurCan uses its...
-
Capital, M&A & Industry Strategy1 month ago
Novartis pays Sironax $125M to acquire platform for crossing the blood-brain barrier
Novartis is paying Sironax $125 million to take up its option on a brain delivery platform, gaining control of technology for getting large molecules to targets...
LncRNA SBF2-AS1 Worsens Heart Injury After Attack via miR-149-5p/PHLPP2 Axis
Stigmatizing language found in over half of primary care patient records
Research report: The Influence of Renal or Hepatic Impairment on the Pharmacokinetics of Iclepertin (BI 425809): Results from Two Phase I Open-Label, Non-randomised, Single Dose, Parallel Design Studies
Novartis buys Synnovation’s PI3Kα inhibitors for $3 billion
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
